553 related articles for article (PubMed ID: 35670004)
1. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
Niegisch G
Methods Mol Biol; 2023; 2684():293-301. PubMed ID: 37410242
[TBL] [Abstract][Full Text] [Related]
6. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.
Albarrán V; Rosero DI; Chamorro J; Pozas J; San Román M; Barrill AM; Alía V; Sotoca P; Guerrero P; Calvo JC; Orejana I; Pérez de Aguado P; Gajate P
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293515
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
8. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K
Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
10. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
14. [Innovations in systemic treatment of urothelial carcinoma].
Thibault C; Gross-Goupil M
Bull Cancer; 2020 Jun; 107(5S):S6-S16. PubMed ID: 32620209
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
16. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
[TBL] [Abstract][Full Text] [Related]
17. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.
Bianchi A; von Deimling M; Pallauf M; Yanagisawa T; Kawada T; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Majdoub M; Motlagh RS; Pradere B; Karakiewicz PI; Cerruto MA; Antonelli A; Shariat SF
Expert Opin Pharmacother; 2023 Feb; 24(2):177-195. PubMed ID: 36440477
[TBL] [Abstract][Full Text] [Related]
19. [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
Wei T; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
Ceci C; Lacal PM; Graziani G
Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
